Complete and partial responses of the TEMPI syndrome to bortezomib.
Wilfried
W
Schroyens
Casey
C
O'Connell
David B
DB
Sykes
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D004921:Erythropoietin / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010265:Paraproteinemias / Q000188:drug therapy*; D011086:Polycythemia / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D013577:Syndrome; D013684:Telangiectasis / Q000188:drug therapy*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D004921:Erythropoietin; D000069286:Bortezomib